NTLA vs RMD · rev $22.7M vs P/E 29, rev $5.65B
Intellia Therapeutics Inc (NTLA) versus ResMed Inc (RMD) — a side-by-side from cached financials, not a winner call.
Intellia Therapeutics Inc (NTLA) is a biotechnology company listed on US.
ResMed Inc (RMD) is a medical instruments & supplies company listed on US.
Latest reported NTLA revenue for 2026-06-30 was $22.7M. Net income was -$202.9M. Revenue was up 50.9% from 2026-03-31 to 2026-06-30. NTLA currently screens at market cap $1.19B.
Latest reported RMD revenue for 2026-06-30 was $5.65B. Net income was $1.52B. Revenue was up 9.9% from 2025-06-30 to 2026-06-30. RMD currently screens at market cap $37.68B and trailing P/E 28.8.
NTLA currently screens at market cap $1.19B. RMD currently screens at market cap $37.68B and trailing P/E 28.8.
Not investment advice. Open the NTLA and RMD stock pages for the full models.
Not investment advice.